病毒载体製造市场报告：2031 年趋势、预测与竞争分析

全球病毒载体製造市场未来前景光明，在製药、生物製药以及研究机构市场都存在机会。预计到 2031 年全球病毒载体製造市场规模将达到 36 亿美元，2025 年至 2031 年的复合年增长率为 18.7%。该市场的主要驱动因素是对基于病毒载体的疗法的需求不断增加、对病毒载体製造的投资不断增加以及病毒载体製造技术的进步。

• 根据Lucintel的预测，细胞和基因疗法预计将在预测期内实现最高增长，这归因于对细胞和基因疗法的需求不断增加，用于治疗多种疾病，包括癌症、罕见疾病和遗传疾病。
• 基于最终用途产业，随着製药和生物製药公司针对多种疾病（包括癌症、罕见疾病和感染疾病）开发和商业化基于病毒载体的治疗方法，製药和生物製药预计仍将占据最大的份额。
• 根据地区划分，由于北美製药和生物技术行业对基于病毒载体的疗法的需求不断增加，预计预测期内北美将出现最高增长。

病毒载体製造市场的策略性成长机会

由于关键应用中的几个策略机会，病毒载体製造市场正在经历显着成长。这种增长是由技术进步和基因治疗需求的不断增长所推动的，同时治疗应用的前景也在不断扩大。本文重点介绍了五个关键的成长机会领域，并概要了它们对病毒载体製造市场的影响。

• 疫苗开发：利用病毒载体技术的疫苗开发正在市场上迅速扩大。正在利用病毒载体开发针对感染疾病和新兴病原体的疫苗。病毒载体在COVID-19疫苗中的使用证明了其在疫苗开发中的潜力。製造商有机会增强载体技术并扩大生产规模，以帮助生产针对感染疾病、癌症和其他健康状况的新型和改良疫苗。
• 个人化医疗：基于基因的个人化医疗为病毒载体製造提供了新的市场空间。基因编辑和标靶基因转殖等个人化治疗需要病毒载体。随着个人化医疗变得越来越普遍，对于满足特定患者需求的客製化病毒载体的需求也日益增长。可以透过提供灵活的生产解决方案和开发创新的向量系统来利用这一趋势。
• 新市场：病毒载体製造正在为亚太地区和拉丁美洲等新兴市场开闢新的成长途径。这些地区的生物製药产业正在发展，医疗保健方面的投资不断增加，推动了对病毒载体的需求。寻求以更高成长率扩张的公司被迫寻求当地合作伙伴，利用新兴市场条件，在该地区建立生产设施，并有效地驾驭监管环境，以满足对基因和细胞疗法日益增长的需求。

产业扩张受到病毒载体製造市场的策略性成长机会的推动，例如基因和细胞治疗应用、疫苗开发、个人化医疗和新兴市场。我们对这些关键领域的关注将有助于我们扩大市场占有率，同时满足对改善生活药物日益增长的需求。这些机会将继续推动病毒载体製造的成长并塑造未来的方向。

病毒载体製造市场驱动因素与挑战

多种力量和挑战决定了病毒载体製造市场的动态。主要成长动力包括技术创新、对更好的治疗技术的需求不断增加以及金融投资不断增加。相反，该产业也面临生产成本高、监管复杂、技术复杂等缺点。对于这个市场的参与者来说，了解这些因素对于确定克服潜在挑战的最佳策略至关重要。

推动病毒载体製造市场的因素包括：

• 技术进步：技术进步是推动病毒载体製造市场成长的主要力量。自动化、一次性技术和先进的分析能力等创新正在提高製造过程中的效率、扩充性和品质。这些技术改进将使生产商能够透过降低成本同时保持单位时间的生产量来满足对病毒载体日益增长的需求。进一步的技术进步将为提高生产能力和加速新治疗方法的开发提供机会。
• 对更先进药物的需求不断增长：对基因和细胞治疗的需求不断增长是推动市场成长的关键因素。随着越来越多的治疗方法从临床试验转向商业化，需要更好的病毒载体来传递治疗基因。因此，製造商正在扩大生产能力并投资新技术。先进疗法的发展将推动病毒载体製造领域的进一步扩张和创新。
• 增加对生物製药的投资：病毒载体製造市场的成长受到对生物製药产业投资增加的推动。公共和私人资金将促进研发和新製造设施的建立。需要对生物製药基础设施和技术进行投资，以扩大生产规模并增强产能。随着投入的增加，预计病毒载体製造将进一步改善，从而推动市场成长。

病毒载体製造市场挑战包括：

• 生产成本高：病毒载体製造面临高昂的生产成本，这是一个重大挑战。病毒载体製造过程复杂，需要专门的设备和高品质的原料，会产生额外的成本。此外，遵守严格的监管标准会给公司带来财务负担。解决这些成本挑战需要创新製造流程并投资具有成本效益的技术，以确保市场盈利和永续性。
• 监理审批困难：病毒载体製造业面临监理挑战。必须遵守复杂且不断变化的法规来确保产品的安全性和有效性。遵守良好生产规范 (GMP) 指南并获得监管部门核准的成本很高。为了克服这些挑战，製造商必须大力投资能够承受监管变化的品管措施。有效的合规性管理对于维持市场准入和基于病毒载体的治疗方法的成功商业化至关重要。

总之，市场动态受到病毒载体製造市场面临的驱动因素和挑战的影响。虽然市场成长受到技术进步、对先进疗法的需求不断增长以及投资不断增加的推动，但由于製造成本上升和监管障碍，挑战仍然存在。透过技术创新和策略投资克服这些挑战对于市场的持续成功和扩张至关重要。

目录

第一章执行摘要

2. 全球病毒载体製造市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动因素与挑战

第 3 章 市场趋势与预测分析（2019-2031）

• 宏观经济趋势（2019-2024）与预测（2025-2031）
• 全球病毒载体製造市场趋势（2019-2024）与预测（2025-2031）
• 全球病毒载体製造市场按类型划分
  • 腺病毒
  • 逆转录病毒
  • 腺结合病毒
  • 慢病毒
  • 质体DNA
  • 其他的
• 全球病毒载体製造市场（按工作流程）
  • 上游製造业
  • 下游製造
• 全球病毒载体製造市场（按应用划分）
  • 细胞和基因治疗
  • 疫苗学
  • 研究及其他主题
• 全球病毒载体製造市场（按最终用途划分）
  • 製药和生物製药
  • 研究所
  • 其他的

第 4 章区域市场趋势与预测分析（2019-2031 年）

• 全球病毒载体製造市场（按地区）
• 北美洲病毒载体製造市场
• 欧洲病毒载体製造市场
• 亚太病毒载体製造市场
• 世界其他地区的病毒载体製造市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球病毒载体製造市场成长机会（按类型）
  • 全球病毒载体製造市场按工作流程的成长机会
  • 全球病毒载体製造市场的成长机会（按应用）
  • 全球病毒载体製造市场成长机会（按最终用途划分）
  • 全球病毒载体製造市场按地区分類的成长机会
• 全球病毒载体製造市场的新趋势
• 战略分析
  • 新产品开发
  • 全球病毒载体製造市场的产能扩张
  • 全球病毒载体製造市场的企业合併
  • 认证和许可

第七章主要企业简介

• Merck
• Lonza
• FUJIFILM Diosynth Biotechnologies
• Thermo Fisher Scientific
• Cobra Biologics
• Catalent
• Wuxi Biologics
• Takara Bio
• Waisman Biomanufacturing
• Genezen laboratories

The future of the global viral vector manufacturing market looks promising with opportunities in the pharmaceutical & biopharmaceutical and research institutes markets. The global viral vector manufacturing market is expected to reach an estimated $3.6 billion by 2031 with a CAGR of 18.7% from 2025 to 2031. The major drivers for this market are the increasing demand for viral vector-based therapies, growing investment in viral vector manufacturing, and technological advancements in viral vector manufacturing.

• Lucintel forecasts that, within the application category, cell and gene therapy is expected to witness the highest growth over the forecast period due to the growing demand for cell and gene therapies for the treatment of a wide range of diseases, including cancer, rare diseases, and genetic disorders.
• Within the end use industry category, pharmaceutical and biopharmaceutical will remain the largest segment because these pharmaceutical and biopharmaceutical companies are developing and commercializing viral vector-based therapies for a wide range of diseases, including cancer, rare diseases, and infectious diseases.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to increasing demand for viral vector-based therapies from the pharmaceutical and biotechnology industries in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Viral Vector Manufacturing Market

The viral vector manufacturing market is undergoing significant changes, driven by emerging trends that are reshuffling the industry. Some of these trends include progress in production technologies, increased demand for gene and cell therapies, collaboration between private firms and institutions of higher learning, growth of disposable technology platforms, and a notable emphasis on regulatory compliance. While improving productivity and scalability in viral vector manufacturing, these trends also help address issues related to cost structures, quality control, and supply chain challenges.

• Manufacturing Technologies Advancements: A key trend in the viral vector manufacturing market is advancements in manufacturing technologies. The production of viral vectors is being revolutionized by novel inventions like automated production systems, single-use bioreactors, and high-throughput screening. More effective and scalable methods are currently being made possible through these developments, which save time and costs related to production. Additionally, downstream processing and purification methods have advanced, leading to better quality and greater quantities of viral vectors. These advancements will significantly impact manufacturing efficiency as they become more popular, thus contributing to the growth of the market.
• Uneven Surge in Gene and Cell Therapies: A significant factor driving the viral vector manufacturing market's growth is the increasing demand for gene and cell therapies. The requirement for high-quality viral vectors has been driven by the transition of more gene and cell therapies from clinical trials to commercialization. This has prompted manufacturers to expand their production capacity and develop new facilities to cater to the increasing market size. Furthermore, recent successful gene therapies have attracted more investor attention to the industry, leading to increased funding for viral vector manufacturing capabilities. This trend is projected to continue, thereby further expanding the market.
• Advocates for More Collaboration and Partnerships: A major trend in the viral vector manufacturing market is the increased collaboration among pharmaceutical companies, academic institutions, and CMOs. These associations help promote innovation and expedite the development of new viral vector generation methods. These partnerships result in more efficient production processes through the pooling of resources and expertise, as well as the development of new therapies. This is also giving rise to various strategic alliances aimed at expanding manufacturing capabilities while improving the availability of viral vectors. In conclusion, it can be said that increasing partnerships will lead to major market progressions.
• Emphasis on Regulatory Compliance: Another significant trend in viral vector manufacturing is a strong emphasis on regulatory compliance. As the sector expands, manufacturers are increasingly focused on strict regulatory norms that guarantee the safety and effectiveness of their products. These include adherence to Good Manufacturing Practices (GMP) as well as compliance with regional and global regulations. Consequently, a focus on regulatory compliance has led manufacturers to adopt quality control systems, advanced analytics, and efficient documentation procedures. As regulatory demands evolve, keeping pace with them will be vital for drug firms to thrive in the competitive viral vector industry.

The landscape of viral vector manufacturing is changing due to technological advancements, a rise in demand for gene therapies, increased collaborative activities, greater use of single-use technologies, and the importance of regulatory compliance. Innovation propelled by these trends will enhance production efficiency and expand market reach. As such, it is anticipated that this sector will continue to grow while creating new avenues for viral vector manufacturing companies. To maintain momentum and ensure long-term success in the market, continued focus in these areas is crucial.

Recent Developments in the Viral Vector Manufacturing Market

Recent developments in the viral vector manufacturing market have led to significant improvements driven by the increased demand for gene and cell therapies. These developments include advancements in production technology, expansion of manufacturing capacity, and improvements in regulatory compliance procedures. Important changes are occurring with the growth of the market, which intends to concentrate on improving efficiency, scalability, and quality control processes. Such developments enhance viral vector production, yielding better outcomes for therapeutic applications needed by the industry.

• Expansion of Manufacturing Facilities: Recent expansions in manufacturing facilities are crucial for meeting the growing demand for viral vectors. Major biopharmaceutical companies are investing in new production sites and updating existing ones. These efforts aim to expand capacity, enhance scalability, and improve production efficiency. New facilities often incorporate advanced technologies such as automated systems and single-use technologies to streamline processes and ensure high-quality outputs. This development is vital to supporting the increased volume of gene and cell therapies reaching the marketplace and addressing supply chain challenges.
• Embracing Advanced Concepts: Viral vector manufacturing is evolving due to the adoption of advanced technologies. Examples include, but are not limited to, automation, AI, and high-throughput screening. The manufacturing process is simplified using automated systems, thus reducing human error and increasing output. Process optimization and quality control can be enhanced through AI and machine learning. These technologies also enable higher yields and faster production cycles that meet the rising demand for viral vectors in support of advanced therapeutic solutions.
• Novel Viral Vectors Development: The emergence of new viral vectors is expanding gene therapy options. This is achieved by creating brand-new viral vector systems with superior safety profiles, improved transduction efficiencies, and enhanced tissue targeting. These improvements address traditional vector limitations, including low tissue specificity or immune responses. In general, novel vectors facilitate better-targeting approaches for a variety of genetic disorders and cancers. This development thus expands the spectrum of therapeutic applications, leading to further progress in the gene therapy sector.
• Increased Emphasis on Quality and Compliance: The viral vector manufacturing market is being shaped by a heightened emphasis on quality and regulatory compliance. Manufacturers are investing in robust quality control mechanisms that enforce strict regulatory standards to ensure product safety and efficacy. This includes the adoption of Good Manufacturing Practice (GMP) guidelines and advanced analytical methods for process monitoring. Enhanced quality assurance practices help prevent contamination, ensuring that products remain consistently high-quality, which is vital for regulatory approvals and maintaining confidence in viral vector-based therapeutics.

The viral vector manufacturing market is currently experiencing significant developments such as facility expansions, new vector development, quality improvements, and the rise of partnerships, all of which are having a substantial impact on the industry. These changes will enhance manufacturing capacity, efficiency, and quality, which are critical factors for meeting the growing needs for gene and cell therapies. With further development expected as the market continues to evolve, these advances will be instrumental in driving growth and innovation, thereby positioning viral vector production for continued prosperity.

Strategic Growth Opportunities for Viral Vector Manufacturing Market

The viral vector manufacturing market is witnessing substantial growth due to several strategic opportunities across key applications. This progression has been driven by increased technological advancements and demand for gene therapies, while the therapeutic application horizon has prospered. This discussion presents five major areas where there are growth opportunities, outlining their impacts on the viral vector manufacturing market.

• Vaccine Development: * Within the marketplace, vaccine development through viral vector technology has emerged as a rapidly expanding field. Vaccines for infectious diseases and emerging pathogens are being developed using viral vectors. The use of viral vectors in COVID-19 vaccines has demonstrated their potential in vaccine development. Manufacturers have an opportunity to enhance vector technologies and scale up production to help produce new and improved vaccines targeting infectious diseases, cancer, and other health conditions.
• Personalized Medicine: Genetic-based personalized medicine offers a new market niche for viral vector manufacturing. Personalized therapies, such as gene editing or targeted gene delivery, require viral vectors. As individualized medicine becomes more common, there is a growing demand for customized viral vectors that address particular patient needs. This trend can be exploited by offering flexible production solutions and developing innovative vector systems.
• New Markets: Viral vector manufacturing is opening up new avenues of growth in emerging markets like Asia-Pacific and Latin America. The demand for viral vectors is rising as these regions develop their biopharmaceutical sectors and invest more in healthcare. This desire to expand at a higher rate has compelled businesses to seek local partners, take advantage of the emerging market landscape, establish regional production facilities, and navigate regulatory frameworks effectively to meet the increasing demand for gene and cell therapies.

Industry expansion has been driven by strategic growth opportunities in the viral vector manufacturing market, such as gene and cell therapy applications, vaccine development, personalized medicine, and emerging markets. Market presence can be improved by focusing on these important areas while responding to the increased demand for life-improving medications. These opportunities will continue to drive growth in viral vector manufacturing, shaping its future course.

Viral Vector Manufacturing Market Driver and Challenges

Several forces and challenges define the dynamics of the viral vector manufacturing market. Some of the primary growth drivers include innovation, increasing demand for better treatment techniques, and greater financial investments. Conversely, the industry faces drawbacks such as high production costs, regulatory complications, and technical intricacies. For players in this market, understanding these factors is crucial for determining the best strategies to overcome potential challenges.

The factors driving the viral vector manufacturing market include:

• Technological Advancements: Technological advancements have been a major force driving growth in the viral vector manufacturing market. Innovations such as automation, single-use technologies, and advanced analytical capabilities have improved efficiency, scalability, and quality during production. These technological improvements reduce costs while ensuring greater output per unit of time, enabling producers to meet the rising demand for viral vectors. As technology advances further, it will also offer opportunities for enhancing production capacity and facilitating new therapeutic development activities.
• Growing Demand for More Advanced Drugs: The increasing demand for gene and cell therapies is a key factor driving market growth. The rising number of therapies transitioning from clinical trials to commercialization requires better viral vectors to deliver therapeutic genes. Consequently, this prompts manufacturers to expand their production capacities and invest in new technologies. Further expansion and innovation in the viral vector manufacturing sector will be driven by the growth of advanced therapies.
• Increasing Investment in Biopharmaceuticals: The growth of the viral vector manufacturing market is fueled by increased investment in the biopharmaceutical industry. Funding from public and private sectors facilitates research and development as well as the establishment of new manufacturing facilities. Investments in biopharmaceutical infrastructure and technology are necessary to scale up production and enhance capabilities. With rising levels of investment, further improvements in viral vector manufacturing are expected, leading to market growth.

Challenges in the viral vector manufacturing market include:

• High Cost of Production: Viral vector manufacturing faces high production costs, which is a major challenge. Additional costs arise from the complexities of the viral vector production process, which requires specialized equipment and high-quality raw materials. Furthermore, compliance with strict regulatory standards adds a financial burden on companies. Addressing these cost challenges necessitates innovations in manufacturing processes and investments in cost-effective technologies to ensure profitability and sustainability within the market.
• Difficulties in Regulatory Clearance: The viral vector manufacturing industry faces challenges related to regulation. The safety and efficacy of products must be ensured through adherence to complex and ever-changing regulations. Costs are incurred when complying with Good Manufacturing Practice (GMP) guidelines and obtaining regulatory approvals. To overcome these challenges, manufacturers should invest heavily in quality control measures that can withstand regulatory changes. Efficient management of compliance is critical for maintaining access to markets and successfully commercializing therapies based on viral vectors.

In conclusion, market dynamics are shaped by the drivers and challenges facing the viral vector manufacturing market. Market growth is propelled by technological advancements, rising demand for advanced therapies, and increased investments, while challenges persist related to high production costs and regulatory hurdles. Overcoming these challenges through innovation and strategic investments will be essential for the continued success and expansion of the market.

List of Viral Vector Manufacturing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies viral vector manufacturing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the viral vector manufacturing companies profiled in this report include-

• Merck
• Lonza
• Fujifilm Diosynth Biotechnologies
• Thermo Fisher Scientific
• Cobra Biologics
• Catalent
• Wuxi Biologics
• Takara Bio
• Waisman Biomanufacturing
• Genezen Laboratories

Viral Vector Manufacturing by Segment

The study includes a forecast for the global viral vector manufacturing market by type, workflow, application, end use, and region.

Viral Vector Manufacturing Market by Type [Analysis by Value from 2019 to 2031]:

• Adenovirus
• Retrovirus
• Adeno-Associated Virus
• Lentivirus
• Plasmid DNA
• Others

Viral Vector Manufacturing Market by Workflow [Analysis by Value from 2019 to 2031]:

• Upstream Manufacturing
• Downstream Manufacturing

Viral Vector Manufacturing Market by Application [Analysis by Value from 2019 to 2031]:

• Cell & Gene Therapy
• Vaccinology
• Research & Other Applications

Viral Vector Manufacturing Market by End Use [Analysis by Value from 2019 to 2031]:

• Pharmaceutical & Biopharmaceutical
• Research Institutes
• Others

Viral Vector Manufacturing Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Viral Vector Manufacturing Market

Viral vector manufacturing is a global market that is growing rapidly due to the increased demand for gene therapies, vaccines, and cell-based treatments. In these processes, viral vectors are used as agents to introduce genetic materials into the cells where they should be placed. In key economies, including the United States, China, Germany, India, and Japan, there have been considerable developments in manufacturing capabilities, regulatory approvals, and technological innovations, among others.

• United States: The growth of viral vector manufacturing in the country is attributable to the increasing usage of gene therapies and vaccines. Major biopharmaceutical companies and contract development and manufacturing organizations (CDMOs) are expanding their production facilities in response to the growing demand. New plants are being constructed, and existing ones are being retrofitted with new technologies to enhance capacity and ensure compliance with GMP standards. These actions bolster America's ability to produce scalable, high-quality viral vectors, establishing it as a global leader and a role model in manufacturing prowess.
• China: In China, the viral vector manufacturing sector is rapidly changing due to strong governmental efforts to enhance biotechnology and gene therapy sectors. The Chinese authorities have made significant investments in biopharmaceutical infrastructure, particularly in viral vector manufacturing facilities. Furthermore, provincial enterprises are adopting high-end production technologies for increased productivity and quality improvement. This collaboration between academia and industry has spurred innovation in viral vectors. Consequently, these trends position China as one of the main global players, with increasing capacity to meet both local and foreign demand for viral vectors.
• Germany: In terms of viral vector manufacturing, Germany leads in innovation while maintaining high standards of quality control and advanced manufacturing processes. German companies are investing in cutting-edge technologies such as automated production systems and single-use bioreactors, which have improved the efficiency and scalability of viral vector production. Additionally, its stringent regulatory framework ensures that manufacturing processes meet the highest quality standards, solidifying Germany's position as a major player in Europe and enhancing its global competitiveness in the biopharmaceutical sector.
• India: India is becoming a formidable force in the viral vector manufacturing market, especially in contract manufacturing. Its skilled labor force and lower production costs make it an attractive destination for outsourcing viral vector production. Indian companies are increasing their manufacturing capacity by investing in new plants and adopting cutting-edge technologies to meet the growing global demand for viral vectors. Moreover, India's regulatory environment is being aligned with international standards, further enhancing its appeal as a leading center for viral vector manufacturing. Thus, India is now positioned as a major supplier on the global market stage.
• Japan: Japan's viral vector manufacturing market is characterized by a blend of emerging technologies and substantial research and development focus. AI and automation are leading ventures for innovation in this field, being undertaken by Japanese companies to enhance accuracy and efficiency in viral vector manufacturing. Furthermore, Japan has a mature regulatory framework that facilitates the rapid development and commercialization of novel therapies. These aspects position Japan as a major player in the viral vector market, leading its competitors in technology advancement and ensuring its competitiveness in the global market.

Features of the Global Viral Vector Manufacturing Market

Market Size Estimates: Viral vector manufacturing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Viral vector manufacturing market size by various segments, such as by type, workflow, application, end use, and region in terms of value ($B).

Regional Analysis: Viral vector manufacturing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, workflows, applications, end uses, and regions for the viral vector manufacturing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the viral vector manufacturing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the viral vector manufacturing market by type (adenovirus, retrovirus, adeno-associated virus, lentivirus, plasmid DNA, and others), workflow (upstream manufacturing and downstream manufacturing), application (cell & gene therapy, vaccinology, and research & other applications), end use (pharmaceutical & biopharmaceutical, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Viral Vector Manufacturing Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Viral Vector Manufacturing Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Viral Vector Manufacturing Market by Type
  • 3.3.1: Adenovirus
  • 3.3.2: Retrovirus
  • 3.3.3: Adeno-Associated Virus
  • 3.3.4: Lentivirus
  • 3.3.5: Plasmid DNA
  • 3.3.6: Others
• 3.4: Global Viral Vector Manufacturing Market by Workflow
  • 3.4.1: Upstream Manufacturing
  • 3.4.2: Downstream Manufacturing
• 3.5: Global Viral Vector Manufacturing Market by Application
  • 3.5.1: Cell & Gene Therapy
  • 3.5.2: Vaccinology
  • 3.5.3: Research & Other Applications
• 3.6: Global Viral Vector Manufacturing Market by End Use
  • 3.6.1: Pharmaceutical & Biopharmaceutical
  • 3.6.2: Research Institutes
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Viral Vector Manufacturing Market by Region
• 4.2: North American Viral Vector Manufacturing Market
  • 4.2.1: North American Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
  • 4.2.2: North American Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
• 4.3: European Viral Vector Manufacturing Market
  • 4.3.1: European Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
  • 4.3.2: European Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
• 4.4: APAC Viral Vector Manufacturing Market
  • 4.4.1: APAC Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
  • 4.4.2: APAC Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
• 4.5: ROW Viral Vector Manufacturing Market
  • 4.5.1: ROW Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
  • 4.5.2: ROW Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Viral Vector Manufacturing Market by Type
  • 6.1.2: Growth Opportunities for the Global Viral Vector Manufacturing Market by Workflow
  • 6.1.3: Growth Opportunities for the Global Viral Vector Manufacturing Market by Application
  • 6.1.4: Growth Opportunities for the Global Viral Vector Manufacturing Market by End Use
  • 6.1.5: Growth Opportunities for the Global Viral Vector Manufacturing Market by Region
• 6.2: Emerging Trends in the Global Viral Vector Manufacturing Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Viral Vector Manufacturing Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Viral Vector Manufacturing Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Merck
• 7.2: Lonza
• 7.3: FUJIFILM Diosynth Biotechnologies
• 7.4: Thermo Fisher Scientific
• 7.5: Cobra Biologics
• 7.6: Catalent
• 7.7: Wuxi Biologics
• 7.8: Takara Bio
• 7.9: Waisman Biomanufacturing
• 7.10: Genezen laboratories